<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">Tocilizumab is used in autoimmune diseases such as rheumatoid arthritis and multiple myoloma and it is a human recombinant IL-6 receptor (IL-6R) antibody [
 <xref rid="bb0685" ref-type="bibr">137</xref>]. It is associated with major side effects such as allergy, liver toxicity and hyperlipidaemia [
 <xref rid="bb0690" ref-type="bibr">138</xref>]. IL-6 is involved in the activation of various immunological and inflammatory mediators, which are responsible for respiratory collapse observed in SARS-CoV-2 infected patients. Tocilizumab is under phase II clinical trials and tested for SARS-CoV-2 induced pneumonia (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04317092" id="ir0300" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04317092</ext-link>).
</p>
